Sintilimab is marketed as TYVYT (sintilimab injection) in China. Credit: Mufid Majnun on Unsplash.

Innovent Biologics and Eli Lilly and Company have announced approval by the National Medical Products Administration (NMPA) of China for the supplemental New Drug Application (sNDA) for a combination therapy to treat patients with epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC) who progressed after EGFR tyrosine kinase inhibitor (TKI) therapy.

The approval was given to TYVYT (sintilimab injection) plus bevacizumab and chemotherapy (pemetrexed and cisplatin).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This is the seventh indication of TYVYT (sintilimab injection) to be cleared by NMPA.

TYVYT is a PD-1 immunoglobulin G4 monoclonal antibody jointly developed by Innovent Biologics and Eli Lilly and Company.

The regulatory clearance is based on data from the ORIENT-31 Phase III randomised, double-blind, multi-centre trial that assessed TYVYT (sintilimab injection) greater or less than BYVASDA (bevacizumab injection) and chemotherapy (pemetrexed and cisplatin).

The trial’s second interim evaluation showed that significant and clinically meaningful progression-free survival (PFS) was continued with sintilimab plus bevacizumab plus chemotherapy, in comparison with chemotherapy alone, in the intent-to-treat group.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The assessment was made by the independent radiographic review committee.

Major secondary endpoints of objective response rate and duration of response were also found to be improved when patients were treated with sintilimab plus bevacizumab plus chemotherapy, in comparison with chemotherapy alone.

Up to the data cut-off date of 4 July 2022, an overall survival (OS) trend with sintilimab plus bevacizumab and chemotherapy was seen, even though the median OS for chemotherapy was extended because of crossover following progression in the chemotherapy group.

Innovent Biologics founder, chairman and CEO Dr Michael Yu stated: “Despite proven efficacy in broad types of cancer, immunotherapy has rarely made breakthroughs in the treatment of driver gene-positive non-squamous NSCLC patients.

“We are excited about the results of the ORIENT-31 study, and this new approval marks the first immunotherapy combination therapy approved for patients with driver gene-positive non-squamous NSCLC in China, making TYVYT the first PD-1 inhibitor approved for driver gene-positive non-squamous NSCLC globally.”